Y0000515

Glimepiride

European Pharmacopoeia (EP) Reference Standard

Synonym(s):
Glimepiride
Empirical Formula (Hill Notation):
C24H34N4O5S
CAS Number:
Molecular Weight:
490.62
MDL number:
PubChem Substance ID:
NACRES:
NA.24
Pricing and availability is not currently available.

grade

pharmaceutical primary standard

form

neat

CofA

certificate is enclosed in each package

mfr. no.

EDQM

Featured Industry

Pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CCC1=C(C)CN(C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC@H3CCC@H(C)CC3)C1=O

InChI

1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30)/t16-,19-

InChI key

WIGIZIANZCJQQY-RUCARUNLSA-N

Gene Information

human ... ABCC8(6833), KCNJ11(3767)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Glimepiride is currently used to treat type 2 diabetes.

Biochem/physiol Actions

Glimepiride is a potent blocker of cardiac KATP channels activated by pinacidil with an IC50 of 6.8 nM.

Packaging

Unit quantity: 110 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Caution

Other Notes

Sales restrictions may apply.

Pictograms

Health hazard

Signal Word

Warning

Hazard Statements

RIDADR

NONH for all modes of transport

WGK Germany

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
M Nauck et al.
Diabetes, obesity & metabolism, 15(3), 204-212 (2012-09-19)
To investigate efficacy and safety of dual therapy with liraglutide and metformin in comparison to glimepiride and metformin, and metformin monotherapy over 2 years in patients with type 2 diabetes. In the 26-week the Liraglutide Effect and Action in Diabetes...
H D Langtry et al.
Drugs, 55(4), 563-584 (1998-04-30)
Glimepiride is a sulphonylurea agent that stimulates insulin release from pancreatic beta-cells and may act via extrapancreatic mechanisms. It is administered once daily to patients with type 2 (non-insulin-dependent) diabetes mellitus in whom glycaemia is not controlled by diet and...
Rudy Bonfilio et al.
Therapeutic drug monitoring, 32(5), 550-559 (2010-08-26)
Glimepiride is an oral antidiabetic drug in the sulfonylurea class, which is widely used in treatment of Type 2 diabetes and it is currently available in more than 60 countries worldwide. As a result of the importance of this oral...
Giuseppe Derosa et al.
Metabolism: clinical and experimental, 63(7), 957-967 (2014-05-31)
To evaluate the effects of vildagliptin compared to glimepiride on glycemic control, insulin resistance and post-prandial lipemia. 167 type 2 diabetic patients, not adequately controlled by metformin, were randomized to vildagliptin 50 mg twice a day or glimepiride 2 mg...
Massimo Massi-Benedetti
Clinical therapeutics, 25(3), 799-816 (2003-07-11)
Sulfonylureas (SUs) have been used for many years as first-line therapy for patients with type 2 diabetes mellitus whose blood glucose levels have not been effectively controlled by diet and exercise alone. Glimepiride is a once-daily SU that was introduced...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.